<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Diagnostic approach, differential diagnosis, and management of a small renal mass
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Diagnostic approach, differential diagnosis, and management of a small renal mass
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Diagnostic approach, differential diagnosis, and management of a small renal mass
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Phillip M Pierorazio, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Steven C Campbell, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jerome P Richie, MD, FACS
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael B Atkins, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sonali M Shah, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 07, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1374815367">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Small renal masses (SRMs; &lt;4 cm) suspicious for clinical stage T1a renal cell carcinoma (RCC) are among the most common kidney tumors encountered in clinical practice  (
         <a class="graphic graphic_table graphicRef110735" href="/z/d/graphic/110735.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
         The detection of SRMs has increased due to the increased use of imaging tests, such as ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI), performed for unrelated indications [
         <a href="#rid3">
          3,4
         </a>
         ]. Despite the high incidence of such masses, mortality rates from RCC have remained stable or decreased slightly in developed countries.
        </p>
        <p>
         SRMs of indeterminate significance represent a heterogeneous group of lesions that range from benign masses and cysts to indolent and aggressive malignancies. SRMs and complex cystic masses (typically with a solid enhancing component) are more likely to be malignant and warrant further evaluation. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         below.)
        </p>
        <p>
         The initial evaluation, differential diagnosis, diagnostic approach, and treatment of SRMs suspicious for malignancy will be reviewed here. The approach outlined in this topic is consistent with guidelines from the American Urological Association (AUA) [
         <a href="#rid5">
          5,6
         </a>
         ].
        </p>
        <p>
         The evaluation of RCC in general and kidney cysts are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2983.html" rel="external">
          "Clinical manifestations, evaluation, and staging of renal cell carcinoma"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1681.html" rel="external">
          "Simple and complex kidney cysts in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3183070504">
         <span class="h1">
          DEFINITION
         </span>
         <span class="headingEndMark">
          —
         </span>
         An SRM suspicious for malignancy is defined as a kidney lesion &lt;4 cm in largest dimension on high-quality, multiphase, cross-sectional abdominal imaging with and without contrast enhancement [
         <a href="#rid5">
          5,6
         </a>
         ]. These lesions are classified as either solid  (
         <a class="graphic graphic_diagnosticimage graphicRef87863" href="/z/d/graphic/87863.html" rel="external">
          image 1
         </a>
         ) or complex cystic (Bosniak class III or IV  (
         <a class="graphic graphic_table graphicRef67087" href="/z/d/graphic/67087.html" rel="external">
          table 2
         </a>
         ))  (
         <a class="graphic graphic_diagnosticimage graphicRef87864" href="/z/d/graphic/87864.html" rel="external">
          image 2
         </a>
         ) based on their imaging appearance. (See
         <a class="local">
          'Dedicated kidney imaging'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/1681.html" rel="external">
          "Simple and complex kidney cysts in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H213085097">
         <span class="h2">
          Dedicated kidney imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Optimal imaging to assess an incidental kidney lesion utilizes dedicated kidney computed tomography (CT) or magnetic resonance imaging (MRI), without and then with intravenous contrast administration.
        </p>
        <p class="headingAnchor" id="H4003520031">
         <span class="h3">
          CT versus MRI
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data suggest that both CT and MRI have similar diagnostic accuracy [
         <a href="#rid7">
          7
         </a>
         ]. SRMs with a cystic component present on the original imaging evaluation can be evaluated using either a dedicated kidney CT scan or MRI. If a CT scan is obtained, the lesion can be characterized using the Bosniak criteria  (
         <a class="graphic graphic_table graphicRef67087" href="/z/d/graphic/67087.html" rel="external">
          table 2
         </a>
         ), which were originally based upon CT findings. If an MRI is obtained, MRI-based criteria for the classification of complex kidney cysts are also available [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         Ultimately, the choice between CT and MRI for the workup of a complicated cystic or solid kidney mass should be based upon the locally available scanner, managing clinician preference, radiologist expertise, potential contraindications to the various contrast agents, and costs. Other factors that may influence the choice of imaging procedure include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Features favoring the use of CT
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Rapid image acquisition, which may be a consideration for patients with claustrophobia or other factors that preclude lying still for an MRI, which usually takes 20 to 30 minutes.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Compatibility with metallic medical implants (eg, pacemakers and orthopedic prostheses), which may preclude MRI.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ability to obtain a high-resolution quantitative assessment of enhancement using Hounsfield unit measurements, which can be done with CT but not MRI.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Dual-energy CT with material attenuation analysis, if available, may be preferred for SRMs, as it decreases false positive rates [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Features favoring the use of MRI
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         No exposure to radiation, which may be a particular consideration for younger patients.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         MRI may be better for characterization of SRMs, especially those &lt;2 cm in diameter.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Use of gadolinium contrast, which has a much lower risk of an allergic reaction and contrast nephropathy compared with intravenous contrast used with CT.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Additionally, most centers allow patients with severe chronic kidney disease or end-stage kidney disease to proceed with dedicated MRI of the kidneys, which is consistent with recommendations from the American College of Radiology [
         <a href="#rid10">
          10
         </a>
         ]. MRI was previously restricted for patients with estimated glomerular filtration rate (GFR) &lt;30 mL/min per 1.73 m
         <sup>
          2
         </sup>
         due to concern about nephrogenic systemic fibrosis. However, with the use of next-generation gadolinium-based contrast agents  (
         <a class="graphic graphic_table graphicRef119865" href="/z/d/graphic/119865.html" rel="external">
          table 3
         </a>
         ), which prevent the release of gadolinium from chelating agents, nephrogenic systemic fibrosis is extremely uncommon [
         <a href="#rid11">
          11
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/113082.html" rel="external">
          "Patient evaluation before gadolinium contrast administration for magnetic resonance imaging", section on 'Approach to preventing nephrogenic systemic fibrosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1955.html" rel="external">
          "Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced kidney disease", section on 'Prevention'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Other imaging procedures
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Emerging data indicate that contrast-enhanced (microbubble-based) ultrasound may offer another imaging option for patients with severely compromised kidney function.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         While multiphase contrast-enhanced MRI can differentiate the various types of renal cell carcinoma (RCC; eg, clear cell, papillary, or chromophobe) with excellent reader agreement, it is not able to differentiate between clear cell RCCs and oncocytomas [
         <a href="#rid12">
          12
         </a>
         ]. Technetium-99m sestamibi single-photon emission computed tomography (SPECT)/CT imaging has demonstrated promising results in distinguishing renal oncocytoma and hybrid oncocytic/chromophobe tumors, which tend to be very indolent, from clear cell RCC, although these data await large-scale validation [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1769427331">
         <span class="h3">
          Imaging characteristics
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following imaging-based characteristics are used to describe kidney masses:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Presence of fat
         </strong>
         – The presence of fat on CT is characterized as a density measured by Hounsfield units that is less than water or soft tissue (ie, ≤10 Hounsfield units)  (
         <a class="graphic graphic_diagnosticimage graphicRef50146" href="/z/d/graphic/50146.html" rel="external">
          image 3
         </a>
         ). A distinct area with less than -20 Hounsfield units in a kidney mass is diagnostic for angiomyolipoma, which is a benign kidney neoplasm. It can also be detected on MRI by a loss of high T1 signal on fat-suppression sequences [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/90017.html" rel="external">
          "Renal angiomyolipomas (AMLs): Management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Enhancement
         </strong>
         – Enhancement is characterized on CT as an increase in signal &gt;15 to 20 Hounsfield units after intravenous contrast administration [
         <a href="#rid15">
          15
         </a>
         ]. Enhancement can also be assessed qualitatively on MRI by subtracting the signal intensity on postcontrast images from that on the precontrast images [
         <a href="#rid16">
          16
         </a>
         ]. Absence of enhancement suggests that the lesion is more likely benign, while enhancement suggests a greater risk of malignancy. However, benign oncocytomas often demonstrate enhancement patterns similar to clear cell RCC.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Characteristics of a cystic component
         </strong>
         – Cystic lesions are characterized by the Bosniak criteria, which are defined based upon CT findings [
         <a href="#rid17">
          17
         </a>
         ]. Although not yet validated for reader agreement or generalizability [
         <a href="#rid18">
          18
         </a>
         ], these criteria have been widely adopted to classify kidney cysts as definitely benign (type I and II), likely benign (type IIF), or likely malignant (type III and IV). (See
         <a class="medical medical_review" href="/z/d/html/1681.html" rel="external">
          "Simple and complex kidney cysts in adults", section on 'Bosniak classification of kidney cysts'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tumor complexity
         </strong>
         – In general, tumor complexity describes the size and approximation of the kidney mass to the central or hilar structures of the kidney. A number of objective systems exist to classify complexity, including the RENAL nephrometry score, the Padua Prediction Score, and the C-index. Categorization as low or high complexity may be useful for selection of type of surgery and surgical approach and may also provide an estimate for risk of surgical complications [
         <a href="#rid19">
          19-21
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3217684825">
         <span class="h1">
          RISK OF MALIGNANCY
         </span>
         <span class="headingEndMark">
          —
         </span>
         SRMs with contrast enhancement or a complex cystic structure are important because of the risk of malignancy. The majority of these lesions are malignant, but a significant proportion are benign and only a small proportion are aggressive malignancies.
        </p>
        <p>
         Increasing tumor size and male sex are the best predictors of malignancy, higher tumor grade, and higher pathologic stage [
         <a href="#rid22">
          22
         </a>
         ]. For contrast-enhancing SRMs &lt;2 cm, 20 to 40 percent are benign tumors, less than 10 percent are high-grade renal cell carcinoma (RCC), and less than 1 percent will present with or develop metastatic RCC  (
         <a class="graphic graphic_table graphicRef87865" href="/z/d/graphic/87865.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid23">
          23-25
         </a>
         ]. By contrast, for kidney masses ≥4 cm, only 5 to 10 percent are benign, and upwards of 20 to 30 percent are high-grade or advanced RCC [
         <a href="#rid25">
          25-27
         </a>
         ].
        </p>
        <p>
         Females have an approximately two- to threefold increased likelihood of benign pathology compared with males with comparably sized tumors, although the majority of contrast-enhancing SRMs in females are malignant [
         <a href="#rid28">
          28
         </a>
         ]. Central tumor location may also indicate a higher risk of malignancy or aggressive behavior, but this finding has not been rigorously established [
         <a href="#rid29">
          29
         </a>
         ]. Put in context, a female with a peripherally located kidney mass &lt;3 cm has only a 65 percent chance of having RCC and a less than 10 percent risk of harboring unfavorable pathology; a male with a centrally located kidney mass 3 to 4 cm has a 90 percent risk of RCC and a 35 percent risk of unfavorable pathology [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
         While male sex, tumor size, and tumor location have implications for diagnosis, tumor histology, and pathology, there are no clinical or radiographic features of solid or complex cystic masses that accurately predict biologic behavior.
        </p>
        <p class="headingAnchor" id="H1061683449">
         <span class="h1">
          NATURAL HISTORY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The natural history of most contrast-enhancing SRMs is one of very slow progression. A meta-analysis that incorporated retrospective data from 234 SRMs suspicious for malignancy in 11 series demonstrated an average growth rate of only 0.28 cm per year on observation [
         <a href="#rid31">
          31
         </a>
         ]. Prospective active surveillance programs confirm slow growth rates (on the order of 0.1 cm per year) and exceedingly low rates of metastatic progression (&lt;1 percent in two to three years) [
         <a href="#rid32">
          32,33
         </a>
         ].
        </p>
        <p>
         However, these favorable outcomes likely reflect a selection bias for small tumors and comorbid patients and represent limited follow-up in most series (mean 30 months). In such tumors, long-term local and metastatic recurrence-free survival rates are likely excellent, regardless of the management strategy selected [
         <a href="#rid5">
          5,6,34
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2983.html" rel="external">
          "Clinical manifestations, evaluation, and staging of renal cell carcinoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4136046574">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The differential diagnosis of SRMs that are suspicious for malignancy includes a biologically heterogeneous group ranging from benign tumors to cancers that can be indolent or aggressive [
         <a href="#rid24">
          24,35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H964928260">
         <span class="h2">
          Renal cell carcinoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         The majority of contrast-enhancing SRMs are renal cell carcinoma (RCC) [
         <a href="#rid25">
          25,36
         </a>
         ]. The major subclassifications of RCC include, but are not limited to, clear cell, papillary, and chromophobe; each subtype has distinct morphologic appearance, clinical characteristics, and prognostic significance [
         <a href="#rid37">
          37
         </a>
         ]. Clear cell RCC is the most common histology (approximately 55 percent of SRMs), followed by papillary (20 percent) and chromophobe (5 percent) RCC. Clear cell RCCs have a variable prognosis, determined by stage and grade. Papillary and chromophobe RCCs &lt;4 cm generally demonstrate an indolent course and have a better prognosis than clear cell tumors [
         <a href="#rid32">
          32,33,35
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2982.html" rel="external">
          "Epidemiology, pathology, and pathogenesis of renal cell carcinoma", section on 'Pathology'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2656484486">
         <span class="h2">
          Benign kidney tumors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Even with a suspicious appearance on initial evaluation, contrast-enhancing SRMs can be benign kidney lesions, and benign lesions are more common in females and with smaller tumors. In a single-institution experience, 311 of 2675 surgically resected tumors were benign [
         <a href="#rid23">
          23
         </a>
         ]. These included oncocytoma (75 percent), angiomyolipoma (11 percent), and metanephric adenoma (3 percent).
        </p>
        <p class="headingAnchor" id="H2166360654">
         <span class="h3">
          Oncocytoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Oncocytoma typically appears on computed tomography (CT) or magnetic resonance imaging (MRI) as a homogeneous, well-circumscribed solid mass, often containing a central scar [
         <a href="#rid38">
          38
         </a>
         ]. However, these features are not sufficiently specific to exclude RCC. (See
         <a class="medical medical_review" href="/z/d/html/2982.html" rel="external">
          "Epidemiology, pathology, and pathogenesis of renal cell carcinoma", section on 'Oncocytomas'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2873409543">
         <span class="h3">
          Angiomyolipoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Angiomyolipomas can be reliably distinguished on imaging as an enhancing mass that contains macroscopic fat and no calcifications  (
         <a class="graphic graphic_diagnosticimage graphicRef50146" href="/z/d/graphic/50146.html" rel="external">
          image 3
         </a>
         ). RCC, particularly the clear cell subtype, can contain microscopic fat, but this can be reliably distinguished from macroscopic fat, as seen in most angiomyolipomas. Small angiomyolipomas with minimal fat, designated fat poor, are difficult to characterize on imaging and generally require further evaluation [
         <a href="#rid39">
          39,40
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/90017.html" rel="external">
          "Renal angiomyolipomas (AMLs): Management"
         </a>
         .)
        </p>
        <p>
         When renal angiomyolipomas are bilateral, patients have an 80 to 90 percent chance of having tuberous sclerosis. Patients with tuberous sclerosis also have an increased frequency of RCC, as approximately 1 to 2 percent will develop this malignancy; hence, surveillance for RCC should be considered in this population. Kidney imaging in this setting is also needed to follow the progress of the angiomyolipomas, which are at a low but increased risk for hemorrhage as they grow [
         <a href="#rid41">
          41
         </a>
         ]. Kidney manifestations of tuberous sclerosis are complex and their management, including their relationship to RCC, are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1684.html" rel="external">
          "Renal manifestations of tuberous sclerosis complex"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2709986898">
         <span class="h3">
          Metanephric adenoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         Metanephric adenomas are rare benign lesions that are more common in females than males [
         <a href="#rid42">
          42,43
         </a>
         ]. Although many cases are initially identified incidentally, some patients present with pain, hematuria, or a palpable mass. Metanephric adenomas are defined by a characteristic histology but may be difficult to distinguish from papillary RCC or epithelial predominant Wilms tumor [
         <a href="#rid44">
          44
         </a>
         ]. Approximately 90 percent of metanephric adenomas contain a
         <em>
          BRAF
         </em>
         V600 mutation [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H668296387">
         <span class="h2">
          Metastatic disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         If a lesion in the kidney is suspected to be a metastasis and if knowledge of the histology of the kidney lesion could affect management, kidney mass biopsy should be considered. This may be particularly important in patients undergoing surveillance after previous definitive treatment for another malignancy who have a solitary lesion in the kidney or in patients presenting with oligometastatic disease and a suspected metastatic lesion in the kidney. More typically, metastases to the kidney present with multiple kidney lesions with borderline enhancement and widespread metastatic disease.
        </p>
        <p>
         However, in patients with a history of a cancer that is not RCC, a solitary lesion in the kidney may represent either metastatic disease or a primary kidney tumor. In a series of 2340 patients with a primary cancer other than RCC, 36 (1.5 percent) had a kidney lesion concomitantly diagnosed [
         <a href="#rid46">
          46
         </a>
         ]. Of these, 21 (58 percent) were due to metastatic disease to the kidney; in the remaining 15 (42 percent), there was a concomitant RCC.
        </p>
        <p class="headingAnchor" id="H8184862">
         <span class="h2">
          Lymphoma
         </span>
         <span class="headingEndMark">
          —
         </span>
         When hematologic malignancy involvement of the kidney is a possibility and the histopathology of the kidney lesion may affect management, percutaneous biopsy should be considered to obtain a pathologic diagnosis.
        </p>
        <p>
         Kidney involvement with hematologic malignancies is found at autopsy in approximately 34 percent of patients dying of progressive lymphoma or leukemia, but it is uncommon in clinical practice as kidney involvement is often silent and a late manifestation of systemic disease [
         <a href="#rid47">
          47
         </a>
         ]. Kidney lymphoma should be suspected in patients with massive retroperitoneal lymphadenopathy, splenomegaly, or lymphadenopathy in other regions of the body or in atypical regions within the retroperitoneum.
        </p>
        <p class="headingAnchor" id="H3468996449">
         <span class="h2">
          Kidney abscess or focal pyelonephritis
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of inflammatory and infectious conditions can mimic RCC and can pose a significant diagnostic challenge [
         <a href="#rid48">
          48
         </a>
         ]. These include acute and chronic pyelonephritis and abscess. Perirenal inflammatory changes are common on axial imaging, and careful interpretation of clinical symptoms (ie, chills, fever, flank pain, pyuria) can aid in the diagnosis [
         <a href="#rid49">
          49
         </a>
         ]. Kidney mass biopsy or aspiration with drain placement can also be utilized in this setting, or patients can be followed with serial imaging that should demonstrate resolution of the suspected mass with appropriate antibiotic therapy. (See
         <a class="medical medical_review" href="/z/d/html/8057.html" rel="external">
          "Renal and perinephric abscess"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H321553421">
         <span class="h1">
          MANAGEMENT APPROACH
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no single approach to the management of SRMs, and management decisions require consideration of all of the patient- and tumor-specific features in an individual case. The primary management options include surgery (generally nephron-sparing surgery), thermal ablation, and active surveillance. Each management strategy has a unique profile of advantages and potential serious harms and risks, including potential deterioration of kidney function.
        </p>
        <p class="headingAnchor" id="H1000696337">
         <span class="h2">
          Initial evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once an SRM has been characterized as suspicious for malignancy based upon dedicated imaging, multiple factors need to be considered and discussed with the patient when planning the diagnostic and therapeutic approach. This process should be led by a urologist experienced in dealing with kidney masses and should include a multidisciplinary team as indicated. Such a team may include (but is not limited to) nephrology, diagnostic and interventional radiology, pathology, medical oncology, and genetics  (
         <a class="graphic graphic_table graphicRef116271" href="/z/d/graphic/116271.html" rel="external">
          table 5
         </a>
         and
         <a class="graphic graphic_table graphicRef117551" href="/z/d/graphic/117551.html" rel="external">
          table 6
         </a>
         ) [
         <a href="#rid5">
          5,6
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tumor biology
         </strong>
         – SRMs suspicious for malignancy often are slow growing, and the risk of metastasis is low even if malignancy is present in the early phases of their natural history.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A comprehensive metabolic panel and complete blood count are indicated as part of the initial evaluation for a possible associated paraneoplastic syndrome, and chest imaging to evaluate for metastatic disease is indicated if malignancy is suspected. While these SRMs are unlikely to develop metastatic disease, a small percentage of patients will present with a small primary lesion and metastatic disease. (See
         <a class="medical medical_review" href="/z/d/html/2983.html" rel="external">
          "Clinical manifestations, evaluation, and staging of renal cell carcinoma", section on 'Paraneoplastic symptoms'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2983.html" rel="external">
          "Clinical manifestations, evaluation, and staging of renal cell carcinoma", section on 'Other imaging studies'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tumor-specific factors
         </strong>
         – The initial imaging may provide important information regarding the probability of malignancy and the likelihood that malignancy, if present, will be aggressive. For patients who have had a biopsy, histology may provide information about the potential aggressiveness of the tumor.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Factors to consider that are associated with a higher risk of malignancy or with aggressive tumor behavior include the size of the lesion (3 to 4 versus &lt;3 cm), a rapid growth rate of the mass (&gt;5 mm/year, if multiple time points are available), imaging characteristics (infiltrative versus noninfiltrative), and the location of the lesion within the kidney and its accessibility for surgical resection.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Lesions &lt;1 cm
         </strong>
         – An incidental lesion &lt;1 cm is unlikely to be further characterized by additional imaging or biopsy, and these patients should be offered surveillance. This size cutoff is accepted by most radiologists and urologists because lesions this small cannot be biopsied and generally have high rates of benign histology. Even for lesions &lt;1 cm that are malignant, almost all will demonstrate indolent tumor biology, with low rates of metastatic progression and slow linear growth rates on active surveillance [
         <a href="#rid24">
          24,25,32,33
         </a>
         ]. Hence, surveillance is the most reasonable course of action for such lesions. (See
         <a class="local">
          'Dedicated kidney imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient-specific factors
         </strong>
         – Factors such as older age, shorter life expectancy, significant comorbidity or frailty, or increased operative risk may lead to a patient preference for active surveillance or thermal ablation rather than nephron-sparing surgery. Male sex is more likely to be associated with malignancy, although even in females the majority of suspicious SRMs are malignant.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Complications of treatment
         </strong>
         – The potential morbidities of each treatment approach need to be discussed with the patient. As examples:
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients opting for active surveillance, regular follow-up imaging is required, which may lead to the eventual need for therapeutic intervention, as well as the risk for subsequent development of metastases.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For thermal ablation, the patient should be aware of the increased risk of local recurrence, the need for more frequent imaging after treatment, and the potential need for treatment of recurrent disease.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For surgery, both the immediate operative risks as well as the potential late effects on kidney function should be taken into account. As an example, partial nephrectomy is associated with the highest rates of clinically significant bleeding and urologic complications (ie, urine leak) compared with other treatments, although such events are still generally uncommon. Radical nephrectomy is also associated with the highest rates of nonurologic complications (likely related to patient comorbidities) and the greatest changes in kidney function.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Kidney function
         </strong>
         – Factors to consider include the risk of future progression to chronic kidney disease, as well as the potential short-term need for dialysis, associated with surgery or thermal ablation. Impaired kidney function or risk factors for chronic kidney disease may lead to a preference for active surveillance or thermal ablation. (See
         <a class="medical medical_review" href="/z/d/html/16406.html" rel="external">
          "Definition and staging of chronic kidney disease in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Kidney function should be assessed for assignment of chronic kidney disease stage if necessary. Serum creatinine and urinalysis will allow for estimation of glomerular filtration rate (GFR) and evaluate for proteinuria. Patients with a positive dipstick test for proteinuria (1 or greater) should undergo confirmation by a quantitative measurement (protein-to-creatinine ratio or albumin-to-creatinine ratio) as part of a focused medical workup for kidney dysfunction [
         <a href="#rid50">
          50
         </a>
         ]. Nephrology consultation should be considered for patients with marginal or impaired kidney function.
        </p>
        <p>
        </p>
        <p>
         These factors need to be integrated with the patient's personal preferences and values in determining the therapeutic approach and deciding whether or not to proceed with a kidney mass biopsy.
        </p>
        <p>
         Examples of how these factors may influence patient decision making include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Partial nephrectomy is often preferred for young patients with substantial life expectancy and without significant comorbidity or risk for kidney function impairment who desire definitive treatment. Imaging and/or histologic findings (if a biopsy is performed) may provide additional guidance. Nonetheless, active surveillance may be an appropriate alternative for those wishing to avoid surgery. (See
         <a class="local">
          'Partial nephrectomy'
         </a>
         below and
         <a class="local">
          'Active surveillance'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Older patients and those with significant comorbidity or frailty are more likely to favor active surveillance over immediate therapeutic intervention, particularly if the SRM is &lt;3 cm. Thermal ablation (cryotherapy, radiofrequency ablation) is an alternative that has a lower risk of complications than surgical excision, but it can be associated with increased local recurrence rates. (See
         <a class="local">
          'Active surveillance'
         </a>
         below and
         <a class="local">
          'Ablative techniques'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1333731072">
         <span class="h2">
          Genetic counseling
         </span>
         <span class="headingEndMark">
          —
         </span>
         Genetic counseling to assess for a hereditary kidney cancer syndrome  (
         <a class="graphic graphic_table graphicRef53600" href="/z/d/graphic/53600.html" rel="external">
          table 7
         </a>
         ) is recommended for the following clinical scenarios:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         All patients with kidney cancer ≤46 years of age.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Multifocal or bilateral lesions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A personal or family history suggesting an inherited kidney cancer syndrome.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A first- or second-degree relative with a history of kidney cancer or a known clinical or genetic diagnosis of a hereditary kidney cancer syndrome (even if kidney cancer has not been observed).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If the patient's pathology demonstrates histologic findings suggestive of a hereditary kidney cancer syndrome.
        </p>
        <p>
        </p>
        <p>
         The presence of an inherited kidney cancer syndrome may be associated with
         <strong>
         </strong>
         other tumor types or clinical conditions. Some inherited kidney cancer syndromes are associated with an increased risk of a second kidney primary tumor; therefore, early diagnosis is important for maintaining as much kidney function as possible. Hereditary kidney cancer also has clinical implications for the patient's family members. Further details on hereditary kidney cancer syndromes are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2948.html" rel="external">
          "Hereditary kidney cancer syndromes"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H887147739">
         <span class="h2">
          Kidney mass biopsy
         </span>
         <span class="headingEndMark">
          —
         </span>
         A percutaneous needle biopsy of a suspicious SRM can provide important information about the nature of the kidney lesion in many cases, which can influence counseling and management [
         <a href="#rid5">
          5,6,51
         </a>
         ]. However, biopsy is not required in all cases, depending on the potential therapeutic approaches under consideration  (
         <a class="graphic graphic_table graphicRef117546" href="/z/d/graphic/117546.html" rel="external">
          table 8
         </a>
         ).
        </p>
        <p>
         Biopsy is usually performed as an outpatient procedure under computed tomography (CT) or ultrasound guidance with conscious sedation and/or local anesthesia. Percutaneous biopsy is generally safe with a low risk of complications such as hematoma, pain, gross hematuria, pneumothorax, and hemorrhage [
         <a href="#rid52">
          52
         </a>
         ]. Seeding of the needle tract with malignant cells has also been described during kidney mass biopsies but is relatively uncommon [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
         A biopsy may help distinguish the histologic subtype and aggressiveness of a tumor and, thus, help guide management. In the absence of a definitive diagnosis, the mass should be managed as a renal cell carcinoma (RCC).
        </p>
        <p>
         Biopsy is indicated:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Whenever the pathology of the kidney lesion is unclear and ascertainment of the etiology of the mass will influence subsequent management. This includes but is not limited to situations where the SRM is suspected to be a metastatic lesion, a manifestation of lymphoma  (
         <a class="graphic graphic_diagnosticimage graphicRef108269" href="/z/d/graphic/108269.html" rel="external">
          image 4
         </a>
         ), or of infectious or inflammatory origin rather than a primary kidney tumor.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients who will be managed with thermal ablation, ideally as a separate procedure, to provide a pathologic diagnosis and to assist in guiding subsequent surveillance.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients who are surgical candidates when confirmation of malignancy is desired by the patient or the surgeon prior to the procedure or if further information may help in the decision-making process.
        </p>
        <p>
        </p>
        <p>
         Biopsy is generally not indicated as part of the initial evaluation:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In young and healthy patients who are not willing to accept the potential uncertainties associated with a false-negative result on kidney mass biopsy and who will choose surgery even if the biopsy is negative for cancer.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For older or frail individuals who will initially be managed with surveillance rather than surgery or thermal ablation regardless of the outcome of a kidney mass biopsy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For SRMs &lt;1 cm and cystic kidney masses, the nondiagnostic rates are significantly higher than for larger solid masses, and the rates of aggressive malignancy are much lower, limiting the utility of kidney mass biopsy in these patients.
        </p>
        <p>
        </p>
        <p>
         In a systematic review of the literature that included data from 2979 patients, kidney mass biopsy had an excellent specificity (96.2 percent), sensitivity (97.5 percent), and positive predictive value (99.8 percent), indicating that a diagnosis of cancer is highly reliable [
         <a href="#rid52">
          52
         </a>
         ].
        </p>
        <p>
         However the clinical utility of kidney mass biopsy is limited by a significant nondiagnostic rate (14 to 15 percent), significant negative predictive value (63 percent, indicating that a benign biopsy does not always indicate the absence of cancer), and poor grade concordance for high-grade disease. In addition, many kidney mass biopsy specimens are read as an "oncocytic renal neoplasm," which is somewhat indeterminate. When surgery is performed for such lesions, most prove to be benign oncocytoma or low-grade, indolent variants of kidney cancer [
         <a href="#rid5">
          5,6
         </a>
         ].
        </p>
        <p>
         A biopsy can render a definitive diagnosis for RCC and benign masses, including angiomyolipoma, metanephric adenoma, or focal infection. However, a diagnosis of oncocytoma, while reassuring, should be viewed with caution, as chromophobe RCC can result in a similar appearance on needle biopsy [
         <a href="#rid54">
          54
         </a>
         ]. If the biopsy yields a nondiagnostic or nonspecific result, a repeat biopsy is a reasonable option. Core needle specimens are preferred and have demonstrated superior diagnostic rates compared with fine needle aspiration [
         <a href="#rid52">
          52
         </a>
         ]. Biopsy or aspiration of complex cystic masses is generally discouraged due to the risk of spillage [
         <a href="#rid5">
          5,6,52
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H105010940">
         <span class="h1">
          MANAGEMENT OPTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is no single approach to the management of SRMs, and management decisions should be made in conjunction with patient counseling based on patient-specific assessment of the oncologic risk of the SRM, the general health and comorbidities, and the efficacy and risk of each intervention, taking into special consideration kidney function  (
         <a class="graphic graphic_table graphicRef116271" href="/z/d/graphic/116271.html" rel="external">
          table 5
         </a>
         ) [
         <a href="#rid5">
          5,6
         </a>
         ]. (See
         <a class="local">
          'Management approach'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1854599389">
         <span class="h2">
          Partial nephrectomy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surgical removal of the tumor with preservation of normal kidney parenchyma (nephron-sparing surgery) is the preferred management strategy for SRMs suspicious for malignancy in patients who are candidates for definitive treatment  (
         <a class="graphic graphic_table graphicRef117547" href="/z/d/graphic/117547.html" rel="external">
          table 9
         </a>
         ) [
         <a href="#rid5">
          5,6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2985.html" rel="external">
          "Definitive surgical management of renal cell carcinoma"
         </a>
         .)
        </p>
        <p>
         Partial nephrectomy is associated with favorable oncologic outcomes and minimizes the risk of chronic kidney disease or progressive chronic kidney disease [
         <a href="#rid55">
          55
         </a>
         ]. Partial nephrectomy has the highest risk of perioperative bleeding (approximately 1 to 2 percent incidence) or urinoma formation (approximately 3 to 5 percent incidence) compared with other management options, although the absolute rates are relatively low when performed at experienced centers. Such complications are almost always manageable with conservative measures and typically are associated with good outcomes [
         <a href="#rid5">
          5,6
         </a>
         ].
        </p>
        <p>
         Surgical removal of the entire kidney (ie, radical nephrectomy) is an acceptable option for the management of an SRM when tumor size, kidney mass biopsy, or imaging characteristics (eg, infiltrative appearance) indicate increased oncologic potential. In this setting, radical nephrectomy is preferred if all of the following criteria are also met [
         <a href="#rid5">
          5,6
         </a>
         ]  (
         <a class="graphic graphic_table graphicRef117547" href="/z/d/graphic/117547.html" rel="external">
          table 9
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High tumor complexity such that a partial nephrectomy would be technically challenging (even in experienced hands).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         No preexisting chronic kidney disease or proteinuria.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Normal contralateral kidney and new baseline glomerular filtration rate (GFR) will likely be &gt;45 mL/min/1.73 m
         <sup>
          2
         </sup>
         even if radical nephrectomy is performed.
        </p>
        <p>
        </p>
        <p>
         Patients who do not meet all these criteria should alternatively be evaluated for partial nephrectomy unless there are overriding concerns about the safety and oncologic efficacy of partial nephrectomy.
        </p>
        <p>
         A randomized study demonstrated no difference in oncologic outcomes and small differences in kidney function in over 500 patients randomized to partial and radical nephrectomy with tumors 5 cm or smaller [
         <a href="#rid56">
          56,57
         </a>
         ]. Importantly, patients in this study were in good general health with excellent preoperative kidney function.
        </p>
        <p>
         Systematic reviews of the surgical literature consistently report lower estimated glomerular filtration rates (eGFRs) and higher rates of stage 3 or worse chronic kidney disease in patients undergoing radical nephrectomy [
         <a href="#rid34">
          34,55
         </a>
         ]. In general, radical nephrectomy should be avoided for SRMs, but it may be needed in a small minority of patients with masses involving a more central position in the kidney (eg, hilar location) or infiltrative features on imaging. (See
         <a class="medical medical_review" href="/z/d/html/2985.html" rel="external">
          "Definitive surgical management of renal cell carcinoma", section on 'Radical versus partial nephrectomy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H723729118">
         <span class="h2">
          Ablative techniques
         </span>
         <span class="headingEndMark">
          —
         </span>
         Thermal ablation (cryotherapy or radiofrequency ablation) is an alternative to partial nephrectomy for patients who do not want or are not able to tolerate definitive surgery and who have an SRM &lt;3 cm  (
         <a class="graphic graphic_table graphicRef117548" href="/z/d/graphic/117548.html" rel="external">
          table 10
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/3001.html" rel="external">
          "Radiofrequency ablation, cryoablation, and other ablative techniques for renal cell carcinoma"
         </a>
         .)
        </p>
        <p>
         Ablation of a kidney mass can be accomplished by either freezing (cryoablation) or heating (radiofrequency ablation). A needle biopsy of the kidney mass prior to or concomitant with thermal ablation is strongly encouraged to determine diagnosis and guide surveillance [
         <a href="#rid5">
          5,6
         </a>
         ]. Laparoscopic or percutaneous approaches are feasible, although the favorable perioperative outcomes associated with thermal ablation are likely driven by the percutaneous approach.
        </p>
        <p>
         Percutaneous thermal ablation is typically carried out as an outpatient procedure under conscious sedation and requires a needle applicator to be placed under imaging guidance. After ablation, all patients with malignancy should undergo surveillance to assess for residual or recurrent tumor that would require additional therapy. Thermal ablation is most efficacious in masses &lt;3 cm, where oncologic outcomes are best and complications are less common [
         <a href="#rid5">
          5,6
         </a>
         ].
        </p>
        <p>
         A systematic review of the literature demonstrates a higher rate of local recurrence or persistence with thermal ablation, so in general, partial nephrectomy is preferred when intervention is elected. With thermal ablation, the five-year lesion recurrence-free rate was 93.5 percent. However, recurrence/persistence after thermal ablation can often be managed with repeat ablation, and when this is taken into account, the outcomes approach those achieved with surgery [
         <a href="#rid34">
          34,58,59
         </a>
         ]. Overall, the five-year lesion recurrence-free rate for thermal ablation is approximately 94 percent. The most common complication is ureteral injury [
         <a href="#rid5">
          5,6
         </a>
         ].
        </p>
        <p>
         A number of extracorporeal ablative modalities are also being studied, including stereotactic body radiation therapy (SBRT), microwave treatment, and electroporation, but the data regarding these modalities are preliminary, and they are still best considered investigational [
         <a href="#rid60">
          60
         </a>
         ]. Additional experience will be required to determine the role of these approaches compared with other ablative techniques.
        </p>
        <p class="headingAnchor" id="H2687935106">
         <span class="h2">
          Active surveillance
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with an SRM &lt;1 cm, we suggest active surveillance rather than immediate treatment.
        </p>
        <p>
         For patients with an SRM between 1 and 4 cm, active surveillance is an alternative management approach, particularly for those with masses that are thought to be lower risk (eg, &lt;2 cm or those that are predominantly cystic, which tend to be nonaggressive). This option is suitable for such patients who prefer to avoid treatment-induced complications and would tolerate regular imaging studies. Active surveillance is preferred whenever the risks associated with intervention or the competing risks of death outweigh the potential oncologic benefits of active treatment  (
         <a class="graphic graphic_table graphicRef117549" href="/z/d/graphic/117549.html" rel="external">
          table 11
         </a>
         ).
        </p>
        <p>
         Given the indolent biology of most contrast-enhancing SRMs, active surveillance is now considered an acceptable initial management strategy for any patient (regardless of age or comorbidity) with an SRM &lt;2 cm [
         <a href="#rid61">
          61
         </a>
         ], and after evaluating age, comorbidities, suitability for surgery, and patient preferences, it is an option for patients with an SRM up to 4 cm [
         <a href="#rid5">
          5,6
         </a>
         ].
        </p>
        <p>
         While active surveillance protocols have yet to be validated, recommendations for surveillance include initial high-quality axial imaging and baseline metastatic evaluation (labs and chest imaging). Serial imaging (computed tomography [CT], magnetic resonance imaging [MRI], or ultrasound) of the kidney lesion every three to six months is used to establish an acceptable linear growth rate (less than 0.5 cm per year); annual imaging is then recommended every 6 to 12 months after the initial two years of surveillance. Although rare in SRMs, imaging findings that suggest tumor infiltration (eg, invasion of the renal sinus, collecting system, or a branch vein) would also warrant further evaluation for treatment.
        </p>
        <p>
         A meta-analysis of retrospective data and prospective active surveillance programs demonstrated slow linear growth rates (0.1 cm per year on average), low rates of surgical intervention (10 to 15 percent), and exceedingly low rates of metastatic progression in appropriately selected patients with SRMs [
         <a href="#rid32">
          32
         </a>
         ]. Other observational studies also confirm these findings and report average linear growth rates of approximately 0.1 to 0.3 cm per year [
         <a href="#rid62">
          62-66
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3232944586">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119821.html" rel="external">
          "Society guideline links: Cancer of the kidney and ureters"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3740258937">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition of small renal mass
         </strong>
         – A solid, enhancing kidney lesion less than 4 cm in largest dimension on high-quality, multiphase, cross-sectional abdominal imaging with and without contrast enhancement meets criteria for a small renal mass (SRM) suspicious for clinical T1a renal cell carcinoma (RCC)  (
         <a class="graphic graphic_table graphicRef110735" href="/z/d/graphic/110735.html" rel="external">
          table 1
         </a>
         ), as does a Bosniak class III/IV cystic lesion  (
         <a class="graphic graphic_table graphicRef67087" href="/z/d/graphic/67087.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'Definition'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Differential diagnosis
         </strong>
         – The majority of such SRMs are RCCs. However, a significant number of such lesions are benign, and other processes (metastases, inflammation, infection) can also present in this fashion. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial evaluation
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Imaging
         </strong>
         – The initial evaluation should include dedicated kidney imaging (computed tomography [CT] or magnetic resonance imaging [MRI]) in addition to a baseline assessment for metastatic disease and kidney function  (
         <a class="graphic graphic_table graphicRef117551" href="/z/d/graphic/117551.html" rel="external">
          table 6
         </a>
         ). (See
         <a class="local">
          'Dedicated kidney imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Indications for biopsy
         </strong>
         – Percutaneous kidney mass biopsy may be indicated when there is uncertainty about the diagnosis or when knowledge of histology may influence subsequent management; in addition, such a biopsy can often provide additional information about the histology of a primary kidney tumor  (
         <a class="graphic graphic_table graphicRef117546" href="/z/d/graphic/117546.html" rel="external">
          table 8
         </a>
         ). (See
         <a class="local">
          'Kidney mass biopsy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
         – Multiple factors need to be considered when planning the diagnostic and therapeutic approach for an individual patient, and these factors should be integrated with the patient's personal preferences and values  (
         <a class="graphic graphic_table graphicRef116271" href="/z/d/graphic/116271.html" rel="external">
          table 5
         </a>
         ). These include tumor-specific factors, patient-specific factors, potential complications of treatment, and kidney function, as well as the natural history of T1a RCCs. (See
         <a class="local">
          'Initial evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This multidisciplinary process should be led by a urologist experienced in dealing with kidney masses and should take into account the oncologic risks, functional considerations, risk of death from competing causes, comparative harms of intervention, and patient preferences  (
         <a class="graphic graphic_table graphicRef116271" href="/z/d/graphic/116271.html" rel="external">
          table 5
         </a>
         and
         <a class="graphic graphic_table graphicRef117547" href="/z/d/graphic/117547.html" rel="external">
          table 9
         </a>
         and
         <a class="graphic graphic_table graphicRef117548" href="/z/d/graphic/117548.html" rel="external">
          table 10
         </a>
         and
         <a class="graphic graphic_table graphicRef117549" href="/z/d/graphic/117549.html" rel="external">
          table 11
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Small renal mass &lt;1 cm
         </strong>
         – For patients with an SRM &lt;1 cm, we suggest active surveillance rather than immediate treatment (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Active surveillance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Small renal mass between 1 and 4 cm
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Partial nephrectomy
         </strong>
         – For otherwise healthy patients with an SRM between 1 and 4 cm, we suggest partial nephrectomy rather than ablation or active surveillance (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Partial nephrectomy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         However, in the setting of limited data and given the overall good prognosis regardless of management strategy, patients may reasonably opt for one of the alternatives such as:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Active surveillance
         </strong>
         – Some patients may opt for active surveillance, particularly for those with masses thought to be a lower risk (eg, &lt;2 cm or predominantly cystic). This option is suitable for such patients who prefer to avoid treatment-induced complications and would tolerate regular imaging studies  (
         <a class="graphic graphic_table graphicRef117549" href="/z/d/graphic/117549.html" rel="external">
          table 11
         </a>
         ). (See
         <a class="local">
          'Active surveillance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Ablation
         </strong>
         – Patients with an SRM &lt;3 cm may reasonably opt for ablation over partial nephrectomy if they prefer a lower complication rate and would tolerate the possibility of needing repeat intervention. (See
         <a class="local">
          'Ablative techniques'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with limited life expectancy or comorbidities
         </strong>
         – For patients with a limited life expectancy or comorbidities, we generally pursue active surveillance, although ablation may be an option for some such patients with tumors &lt;3 cm. (See
         <a class="local">
          'Active surveillance'
         </a>
         above and
         <a class="local">
          'Ablative techniques'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H305586546">
         <span class="h1">
          ACKNOWLEDGMENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Shauna Duigenan, MD, FRCPC, and Susanna Lee, MD, PhD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Nguyen MM, Gill IS, Ellison LM. The evolving presentation of renal carcinoma in the United States: trends from the Surveillance, Epidemiology, and End Results program. J Urol 2006; 176:2397.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kane CJ, Mallin K, Ritchey J, et al. Renal cell cancer stage migration: analysis of the National Cancer Data Base. Cancer 2008; 113:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Znaor A, Lortet-Tieulent J, Laversanne M, et al. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol 2015; 67:519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Connor SD, Pickhardt PJ, Kim DH, et al. Incidental finding of renal masses at unenhanced CT: prevalence and analysis of features for guiding management. AJR Am J Roentgenol 2011; 197:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campbell SC, Clark PE, Chang SS, et al. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I. J Urol 2021; 206:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campbell SC, Uzzo RG, Karam JA, et al. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-up: AUA Guideline: Part II. J Urol 2021; 206:209.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beer AJ, Dobritz M, Zantl N, et al. Comparison of 16-MDCT and MRI for characterization of kidney lesions. AJR Am J Roentgenol 2006; 186:1639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Silverman SG, Pedrosa I, Ellis JH, et al. Bosniak Classification of Cystic Renal Masses, Version 2019: An Update Proposal and Needs Assessment. Radiology 2019; 292:475.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marin D, Davis D, Roy Choudhury K, et al. Characterization of Small Focal Renal Lesions: Diagnostic Accuracy with Single-Phase Contrast-enhanced Dual-Energy CT with Material Attenuation Analysis Compared with Conventional Attenuation Measurements. Radiology 2017; 284:737.
          </a>
         </li>
         <li class="breakAll">
          American College of Radiology (ACR). ACR Manual on Contrast Media 2020. https://www.acr.org/-/media/ACR/Files/Clinical-Resources/Contrast_Media.pdf.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woolen SA, Shankar PR, Gagnier JJ, et al. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis. JAMA Intern Med 2020; 180:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vargas HA, Chaim J, Lefkowitz RA, et al. Renal cortical tumors: use of multiphasic contrast-enhanced MR imaging to differentiate benign and malignant histologic subtypes. Radiology 2012; 264:779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gorin MA, Rowe SP, Baras AS, et al. Prospective Evaluation of (99m)Tc-sestamibi SPECT/CT for the Diagnosis of Renal Oncocytomas and Hybrid Oncocytic/Chromophobe Tumors. Eur Urol 2016; 69:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park BK. Renal Angiomyolipoma: Radiologic Classification and Imaging Features According to the Amount of Fat. AJR Am J Roentgenol 2017; 209:826.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berland LL, Silverman SG, Gore RM, et al. Managing incidental findings on abdominal CT: white paper of the ACR incidental findings committee. J Am Coll Radiol 2010; 7:754.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Newatia A, Khatri G, Friedman B, Hines J. Subtraction imaging: applications for nonvascular abdominal MRI. AJR Am J Roentgenol 2007; 188:1018.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Israel GM, Bosniak MA. An update of the Bosniak renal cyst classification system. Urology 2005; 66:484.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siegel CL, McFarland EG, Brink JA, et al. CT of cystic renal masses: analysis of diagnostic performance and interobserver variation. AJR Am J Roentgenol 1997; 169:813.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kutikov A, Uzzo RG. The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth. J Urol 2009; 182:844.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tobert CM, Kahnoski RJ, Thompson DE, et al. RENAL nephrometry score predicts surgery type independent of individual surgeon's use of nephron-sparing surgery. Urology 2012; 80:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bruner B, Breau RH, Lohse CM, et al. Renal nephrometry score is associated with urine leak after partial nephrectomy. BJU Int 2011; 108:67.
          </a>
         </li>
         <li class="breakAll">
          Pierorazio PM, Johnson MH, Patel HD, et al. Management of Renal Masses and Localized Renal Cancer, Agency for Healthcare Research and Quality, Rockville 2016.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson RH, Kurta JM, Kaag M, et al. Tumor size is associated with malignant potential in renal cell carcinoma cases. J Urol 2009; 181:2033.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johnson DC, Vukina J, Smith AB, et al. Preoperatively misclassified, surgically removed benign renal masses: a systematic review of surgical series and United States population level burden estimate. J Urol 2015; 193:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frank I, Blute ML, Cheville JC, et al. Solid renal tumors: an analysis of pathological features related to tumor size. J Urol 2003; 170:2217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhindi B, Thompson RH, Lohse CM, et al. The Probability of Aggressive Versus Indolent Histology Based on Renal Tumor Size: Implications for Surveillance and Treatment. Eur Urol 2018; 74:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel HD, Semerjian A, Gupta M, et al. Surgical removal of renal tumors with low metastatic potential based on clinical radiographic size: A systematic review of the literature. Urol Oncol 2019; 37:519.
          </a>
         </li>
         <li class="breakAll">
          Piorarazio PM et al. Management of Renal Masses and Localized Renal Cancer, Rockville 2016.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kutikov A, Smaldone MC, Egleston BL, et al. Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score. Eur Urol 2011; 60:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ball MW, Gorin MA, Bhayani SB, et al. Preoperative predictors of malignancy and unfavorable pathology for clinical T1a tumors treated with partial nephrectomy: a multi-institutional analysis. Urol Oncol 2015; 33:112.e9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chawla SN, Crispen PL, Hanlon AL, et al. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol 2006; 175:425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pierorazio PM, Johnson MH, Ball MW, et al. Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. Eur Urol 2015; 68:408.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jewett MA, Mattar K, Basiuk J, et al. Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol 2011; 60:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pierorazio PM, Johnson MH, Patel HD, et al. Management of Renal Masses and Localized Renal Cancer: Systematic Review and Meta-Analysis. J Urol 2016; 196:989.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson RH, Hill JR, Babayev Y, et al. Metastatic renal cell carcinoma risk according to tumor size. J Urol 2009; 182:41.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pierorazio PM, Patel HD, Johnson MH, et al. Distinguishing malignant and benign renal masses with composite models and nomograms: A systematic review and meta-analysis of clinically localized renal masses suspicious for malignancy. Cancer 2016; 122:3267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Srigley JR, Delahunt B, Eble JN, et al. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol 2013; 37:1469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perez-Ordonez B, Hamed G, Campbell S, et al. Renal oncocytoma: a clinicopathologic study of 70 cases. Am J Surg Pathol 1997; 21:871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim JK, Park SY, Shon JH, Cho KS. Angiomyolipoma with minimal fat: differentiation from renal cell carcinoma at biphasic helical CT. Radiology 2004; 230:677.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lane BR, Aydin H, Danforth TL, et al. Clinical correlates of renal angiomyolipoma subtypes in 209 patients: classic, fat poor, tuberous sclerosis associated and epithelioid. J Urol 2008; 180:836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhatt JR, Richard PO, Kim NS, et al. Natural History of Renal Angiomyolipoma (AML): Most Patients with Large AMLs &gt;4cm Can Be Offered Active Surveillance as an Initial Management Strategy. Eur Urol 2016; 70:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davis CJ Jr, Barton JH, Sesterhenn IA, Mostofi FK. Metanephric adenoma. Clinicopathological study of fifty patients. Am J Surg Pathol 1995; 19:1101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yan J, Cheng JL, Li CF, et al. The findings of CT and MRI in patients with metanephric adenoma. Diagn Pathol 2016; 11:104.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hartman DJ, Maclennan GT. Renal metanephric adenoma. J Urol 2007; 178:1058.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choueiri TK, Cheville J, Palescandolo E, et al. BRAF mutations in metanephric adenoma of the kidney. Eur Urol 2012; 62:917.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel U, Ramachandran N, Halls J, et al. Synchronous renal masses in patients with a nonrenal malignancy: incidence of metastasis to the kidney versus primary renal neoplasia and differentiating features on CT. AJR Am J Roentgenol 2011; 197:W680.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luciano RL, Brewster UC. Kidney involvement in leukemia and lymphoma. Adv Chronic Kidney Dis 2014; 21:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhatt S, MacLennan G, Dogra V. Renal pseudotumors. AJR Am J Roentgenol 2007; 188:1380.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Craig WD, Wagner BJ, Travis MD. Pyelonephritis: radiologic-pathologic review. Radiographics 2008; 28:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67:2089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kutikov A, Smaldone MC, Uzzo RG, et al. Renal Mass Biopsy: Always, Sometimes, or Never? Eur Urol 2016; 70:403.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel HD, Johnson MH, Pierorazio PM, et al. Diagnostic Accuracy and Risks of Biopsy in the Diagnosis of a Renal Mass Suspicious for Localized Renal Cell Carcinoma: Systematic Review of the Literature. J Urol 2016; 195:1340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Renshaw AA, Powell A, Caso J, Gould EW. Needle track seeding in renal mass biopsies. Cancer Cytopathol 2019; 127:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel HD, Druskin SC, Rowe SP, et al. Surgical histopathology for suspected oncocytoma on renal mass biopsy: a systematic review and meta-analysis. BJU Int 2017; 119:661.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patel HD, Pierorazio PM, Johnson MH, et al. Renal Functional Outcomes after Surgery, Ablation, and Active Surveillance of Localized Renal Tumors: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol 2017; 12:1057.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Poppel H, Da Pozzo L, Albrecht W, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol 2011; 59:543.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scosyrev E, Messing EM, Sylvester R, et al. Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. Eur Urol 2014; 65:372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wah TM, Irving HC, Gregory W, et al. Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours. BJU Int 2014; 113:416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Talenfeld AD, Gennarelli RL, Elkin EB, et al. Percutaneous Ablation Versus Partial and Radical Nephrectomy for T1a Renal Cancer: A Population-Based Analysis. Ann Intern Med 2018; 169:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Siva S, Louie AV, Warner A, et al. Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). Cancer 2018; 124:934.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pecoraro A, Rosiello G, Luzzago S, et al. Small Renal Masses With Tumor Size 0 to 2 cm: A SEER-Based Study and Validation of NCCN Guidelines. J Natl Compr Canc Netw 2020; 18:1340.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McIntosh AG, Ristau BT, Ruth K, et al. Active Surveillance for Localized Renal Masses: Tumor Growth, Delayed Intervention Rates, and &gt;5-yr Clinical Outcomes. Eur Urol 2018; 74:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gupta M, Alam R, Patel HD, et al. Use of delayed intervention for small renal masses initially managed with active surveillance. Urol Oncol 2019; 37:18.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kunkle DA, Crispen PL, Chen DY, et al. Enhancing renal masses with zero net growth during active surveillance. J Urol 2007; 177:849.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haramis G, Mues AC, Rosales JC, et al. Natural history of renal cortical neoplasms during active surveillance with follow-up longer than 5 years. Urology 2011; 77:787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang L, Li XS, Zhou LQ. Natural history of small renal masses. Chin Med J (Engl) 2015; 128:1232.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2970 Version 44.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17085111" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The evolving presentation of renal carcinoma in the United States: trends from the Surveillance, Epidemiology, and End Results program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18491376" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Renal cell cancer stage migration: analysis of the National Cancer Data Base.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25449206" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : International variations and trends in renal cell carcinoma incidence and mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21701022" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Incidental finding of renal masses at unenhanced CT: prevalence and analysis of features for guiding management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34115547" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34115531" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-up: AUA Guideline: Part II.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16714654" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Comparison of 16-MDCT and MRI for characterization of kidney lesions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31210616" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Bosniak Classification of Cystic Renal Masses, Version 2019: An Update Proposal and Needs Assessment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28353408" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Characterization of Small Focal Renal Lesions: Diagnostic Accuracy with Single-Phase Contrast-enhanced Dual-Energy CT with Material Attenuation Analysis Compared with Conventional Attenuation Measurements.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28353408" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Characterization of Small Focal Renal Lesions: Diagnostic Accuracy with Single-Phase Contrast-enhanced Dual-Energy CT with Material Attenuation Analysis Compared with Conventional Attenuation Measurements.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31816007" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22829683" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Renal cortical tumors: use of multiphasic contrast-enhanced MR imaging to differentiate benign and malignant histologic subtypes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26386607" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Prospective Evaluation of (99m)Tc-sestamibi SPECT/CT for the Diagnosis of Renal Oncocytomas and Hybrid Oncocytic/Chromophobe Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28726505" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Renal Angiomyolipoma: Radiologic Classification and Imaging Features According to the Amount of Fat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20889105" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Managing incidental findings on abdominal CT: white paper of the ACR incidental findings committee.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17377038" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Subtraction imaging: applications for nonvascular abdominal MRI.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16140062" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : An update of the Bosniak renal cyst classification system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9275902" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : CT of cystic renal masses: analysis of diagnostic performance and interobserver variation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19616235" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22626579" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : RENAL nephrometry score predicts surgery type independent of individual surgeon's use of nephron-sparing surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21087391" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Renal nephrometry score is associated with urine leak after partial nephrectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21087391" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Renal nephrometry score is associated with urine leak after partial nephrectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19286217" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Tumor size is associated with malignant potential in renal cell carcinoma cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25072182" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Preoperatively misclassified, surgically removed benign renal masses: a systematic review of surgical series and United States population level burden estimate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14634382" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Solid renal tumors: an analysis of pathological features related to tumor size.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30017400" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : The Probability of Aggressive Versus Indolent Histology Based on Renal Tumor Size: Implications for Surveillance and Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31202730" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Surgical removal of renal tumors with low metastatic potential based on clinical radiographic size: A systematic review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31202730" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Surgical removal of renal tumors with low metastatic potential based on clinical radiographic size: A systematic review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21458155" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Anatomic features of enhancing renal masses predict malignant and high-grade pathology: a preoperative nomogram using the RENAL Nephrometry score.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25499258" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Preoperative predictors of malignancy and unfavorable pathology for clinical T1a tumors treated with partial nephrectomy: a multi-institutional analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16406965" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : The natural history of observed enhancing renal masses: meta-analysis and review of the world literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25698065" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21477920" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Active surveillance of small renal masses: progression patterns of early stage kidney cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27157369" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Management of Renal Masses and Localized Renal Cancer: Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19450840" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Metastatic renal cell carcinoma risk according to tumor size.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27508947" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Distinguishing malignant and benign renal masses with composite models and nomograms: A systematic review and meta-analysis of clinically localized renal masses suspicious for malignancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24025519" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9255250" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Renal oncocytoma: a clinicopathologic study of 70 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14990834" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Angiomyolipoma with minimal fat: differentiation from renal cell carcinoma at biphasic helical CT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18635231" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Clinical correlates of renal angiomyolipoma subtypes in 209 patients: classic, fat poor, tuberous sclerosis associated and epithelioid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26873836" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Natural History of Renal Angiomyolipoma (AML): Most Patients with Large AMLs&gt;4cm Can Be Offered Active Surveillance as an Initial Management Strategy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7573669" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Metanephric adenoma. Clinicopathological study of fifty patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27784295" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : The findings of CT and MRI in patients with metanephric adenoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17640685" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Renal metanephric adenoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22727996" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : BRAF mutations in metanephric adenoma of the kidney.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21940540" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Synchronous renal masses in patients with a nonrenal malignancy: incidence of metastasis to the kidney versus primary renal neoplasia and differentiating features on CT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24359984" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Kidney involvement in leukemia and lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17449786" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Renal pseudotumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18203942" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Pyelonephritis: radiologic-pathologic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15882252" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27085625" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Renal Mass Biopsy: Always, Sometimes, or Never?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26901507" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Diagnostic Accuracy and Risks of Biopsy in the Diagnosis of a Renal Mass Suspicious for Localized Renal Cell Carcinoma: Systematic Review of the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31116493" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Needle track seeding in renal mass biopsies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28058773" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Surgical histopathology for suspected oncocytoma on renal mass biopsy: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28483780" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Renal Functional Outcomes after Surgery, Ablation, and Active Surveillance of Localized Renal Tumors: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21186077" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23850254" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24053769" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Radiofrequency ablation (RFA) of renal cell carcinoma (RCC): experience in 200 tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29946703" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Percutaneous Ablation Versus Partial and Radical Nephrectomy for T1a Renal Cancer: A Population-Based Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29266183" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33022641" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Small Renal Masses With Tumor Size 0 to 2 cm: A SEER-Based Study and Validation of NCCN Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29625756" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Active Surveillance for Localized Renal Masses: Tumor Growth, Delayed Intervention Rates, and&gt;5-yr Clinical Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30446459" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Use of delayed intervention for small renal masses initially managed with active surveillance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17296355" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Enhancing renal masses with zero net growth during active surveillance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21167561" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Natural history of renal cortical neoplasms during active surveillance with follow-up longer than 5 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25947408" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Natural history of small renal masses.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
